2/25/2014 9:39:56 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced that the DFCI/ALL Consortium will utilize the ClonoSIGHT™ test, the first sequencing-based test for minimal residual disease (MRD) in lymphoid cancers, for clinical care of children with ALL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by